ATE502646T1 - Fgfr agoniste - Google Patents

Fgfr agoniste

Info

Publication number
ATE502646T1
ATE502646T1 AT03702574T AT03702574T ATE502646T1 AT E502646 T1 ATE502646 T1 AT E502646T1 AT 03702574 T AT03702574 T AT 03702574T AT 03702574 T AT03702574 T AT 03702574T AT E502646 T1 ATE502646 T1 AT E502646T1
Authority
AT
Austria
Prior art keywords
fgfr
agonits
agonists
relates
fibroblast
Prior art date
Application number
AT03702574T
Other languages
English (en)
Inventor
Johannes Bange
Axel Ullrich
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27664985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE502646(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02002358A external-priority patent/EP1332761A1/de
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of ATE502646T1 publication Critical patent/ATE502646T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
AT03702574T 2002-01-31 2003-01-30 Fgfr agoniste ATE502646T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35383102P 2002-01-31 2002-01-31
EP02002358A EP1332761A1 (de) 2002-01-31 2002-01-31 Agoniste von Fibroblasten-Wachstumsfaktorrezeptoren
PCT/EP2003/000953 WO2003063893A2 (en) 2002-01-31 2003-01-30 Fgfr agonists

Publications (1)

Publication Number Publication Date
ATE502646T1 true ATE502646T1 (de) 2011-04-15

Family

ID=27664985

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702574T ATE502646T1 (de) 2002-01-31 2003-01-30 Fgfr agoniste

Country Status (11)

Country Link
US (1) US7531304B2 (de)
EP (1) EP1469878B1 (de)
JP (1) JP2005530687A (de)
CN (1) CN100531796C (de)
AT (1) ATE502646T1 (de)
AU (1) AU2003205716B2 (de)
CA (1) CA2473810A1 (de)
DE (1) DE60336452D1 (de)
DK (1) DK1469878T3 (de)
ES (1) ES2363765T3 (de)
WO (1) WO2003063893A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1680140T1 (sl) * 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
WO2005066211A2 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1918376A1 (de) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4-favorisierte Krebs-Zellen Resistenz zu chemotherapeutischen Mitteln
EP2094733A1 (de) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4-antikörper
GB0703652D0 (en) 2007-02-26 2007-04-04 Univ Bradford Method for the allosteric modulation of beta1 integrin
SG193860A1 (en) 2008-06-04 2013-10-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102224170A (zh) * 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
NZ592009A (en) 2008-10-10 2012-11-30 Amgen Inc Fgf21 mutants and uses thereof
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
CN102639700A (zh) 2009-09-30 2012-08-15 哈佛大学校长及研究员协会 通过调节自噬增强基因产物调节自噬的方法
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN102614514B (zh) * 2011-01-26 2014-12-10 王永祥 Glp-1受体激动剂用于治疗疼痛
CA2828890A1 (en) * 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
WO2012158704A1 (en) * 2011-05-16 2012-11-22 Genentech, Inc. Fgfr1 agonists and methods of use
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
TW202229343A (zh) 2020-08-21 2022-08-01 美商健臻公司 Fgfr3抗體及使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA941729B (en) 1993-03-12 1994-10-13 Max Planck Gesellschaft Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US6214795B1 (en) * 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity
DE19802377A1 (de) * 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
WO2000039311A1 (en) 1998-12-31 2000-07-06 Advanced Research And Technology Institute Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
FR2796073B1 (fr) 1999-07-07 2003-08-29 Centre Nat Rech Scient Anticorps anti-idiotypiques des facteurs de croissance des fibroblastes et leur utilisation comme medicaments
CA2384089A1 (en) * 1999-09-08 2001-03-15 Genentech, Inc. Fibroblast growth factor-19 (fgf-19) nucleic acids and polypeptides and methods of use for the treatment of obesity

Also Published As

Publication number Publication date
WO2003063893B1 (en) 2004-07-15
JP2005530687A (ja) 2005-10-13
US20050153878A1 (en) 2005-07-14
ES2363765T3 (es) 2011-08-16
EP1469878B1 (de) 2011-03-23
DE60336452D1 (de) 2011-05-05
WO2003063893A3 (en) 2004-04-08
CA2473810A1 (en) 2003-08-07
DK1469878T3 (da) 2011-07-18
US7531304B2 (en) 2009-05-12
WO2003063893A2 (en) 2003-08-07
AU2003205716B2 (en) 2008-08-21
CN100531796C (zh) 2009-08-26
EP1469878A2 (de) 2004-10-27
CN1638792A (zh) 2005-07-13

Similar Documents

Publication Publication Date Title
DE60336452D1 (de) Fgfr agoniste
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
EA200500782A1 (ru) Лечение геморрагического шока
EA200601239A1 (ru) Замещённые хинолиновые соединения
NO20054957L (no) Subtituerte karboksylsyrer
AU2001272735A1 (en) Novel physiologically active peptide and use thereof
DE60206198D1 (de) Tetrahydrochinolinderivate als muscarinische agonisten
GB0222495D0 (en) Compounds
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
NO20064156L (no) Indazolkarboksamidforbindelser som 5-HT4 receptoragonister
BG108225A (en) Thiohydantoins and use thereof for treating diabetes
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
DK1551803T3 (da) Azabicycloderivater som muskarine receptorantagonister
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EP1978362A3 (de) Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
DE60312474D1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
GB0425548D0 (en) Radiolabelled ligands

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties